Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Madrigal Pharmaceuticals Inc (NQ: MDGL ) 216.77 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Madrigal Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 Next > Is Madrigal Pharmaceuticals Stock a Buy? August 17, 2024 The biotech could be worth a lot more in 10 years. Via The Motley Fool This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock August 14, 2024 One player's minor pain is another's moderate gain. Via The Motley Fool 10 Health Care Stocks With Whale Alerts In Today's Session August 12, 2024 Via Benzinga Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' August 07, 2024 Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. Via Investor's Business Daily Topics Earnings Exposures Financial Is It Too Late to Buy Madrigal Pharmaceuticals Stock? August 05, 2024 Will being the first to its market ensure that its future is bright? Via The Motley Fool Is Madrigal Pharmaceuticals Stock a Buy? May 21, 2024 It's not the most prominent biotech, but it has an important claim to fame. Via The Motley Fool 2 Under-the-Radar Growth Stocks to Consider April 10, 2024 Don't ignore these innovative companies. Via The Motley Fool 1 No-Brainer Growth Stock to Buy Now April 03, 2024 This liver-disease specialist might be significantly undervalued. Via The Motley Fool 7 Biotech Stocks to Keep on Your Clinical Radar July 23, 2024 Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. Via InvestorPlace Is Madrigal Pharmaceuticals a Millionaire Maker? June 30, 2024 Its revenue ramp-up is just starting, and its market looks lucrative. Via The Motley Fool Is Madrigal Pharmaceuticals Stock a Buy? June 28, 2024 The company could become a prominent player in the biotech industry, but that might take a while. Via The Motley Fool The Best Biotech Stock to Invest $1,000 in Right Now June 18, 2024 This stock may not be a slam dunk, but it's looking very promising. Via The Motley Fool Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender June 17, 2024 The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. Via Investor's Business Daily Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. June 16, 2024 Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade. Via The Motley Fool Where Will Madrigal Pharmaceuticals Be in 3 Years? June 15, 2024 The coast is clear for it to grow, for now. Via The Motley Fool Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade June 12, 2024 On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. Via Investor's Business Daily 10 Health Care Stocks With Whale Alerts In Today's Session June 11, 2024 Via Benzinga Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals June 10, 2024 Success isn't guaranteed, but both companies could become big winners. Via The Motley Fool What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? June 05, 2024 Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... Via Benzinga Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH June 05, 2024 Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. Via Investor's Business Daily DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session June 05, 2024 Via Benzinga Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug June 04, 2024 Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease. Via Investor's Business Daily The Week Ahead: What's Next June 02, 2024 The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. Via Talk Markets MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024 May 07, 2024 MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 07, 2024 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session May 03, 2024 Via Benzinga 6 Stocks Positioned to Soar as Investors Focus on MASH April 22, 2024 Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of... Via TheNewswire.com 7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024 April 15, 2024 Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades. Via InvestorPlace Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics April 05, 2024 These businesses should see good times ahead. Via The Motley Fool The 3 Best Biotech Stocks to Buy in April 2024 April 01, 2024 Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. Via InvestorPlace < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.